Literature DB >> 10934212

Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs.

R R Bhatt1, J E Ferrell.   

Abstract

The 90-kDa ribosomal S6 kinases, the p90 Rsks, are a family of intracellular serine/threonine protein kinases distinguished by two distinct kinase domains. Rsks are activated downstream of the ERK1 (p44) and ERK2 (p42) mitogen-activated protein (MAP) kinases in diverse biological contexts, including progression through meiotic and mitotic M phases in Xenopus oocytes and cycling Xenopus egg extracts, and are critical for the M phase functions of Xenopus p42 MAPK. Here we report the cloning and biochemical characterization of Xenopus Rsk2. Xenopus Rsk1 and Rsk2 are specifically recognized by commercially available RSK1 and RSK2 antisera on immunoblots, but both Rsk1 and Rsk2 are immunoprecipitated by RSK1, RSK2, and RSK3 sera. Rsk2 is about 20-fold more abundant than the previously described Xenopus Rsk1 protein; their concentrations are approximately 120 and 5 nm, respectively. Rsk2, like Rsk1, forms a heteromeric complex with p42 MAP kinase. This interaction depends on sequences at the extreme C terminus of Rsk2 and can be disrupted by a synthetic peptide derived from the C-terminal 20 amino acids of Rsk2. Finally, we demonstrate that p42 MAP kinase can activate recombinant Rsk2 in vitro to a specific activity comparable to that found in Rsk2 that has been activated maximally in vivo. These findings underscore the importance of the Rsk2 isozyme in the M phase functions of p42 MAP kinase and provide tools for further examining Rsk2 function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934212     DOI: 10.1074/jbc.M006386200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 2.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

3.  Functional interaction between p90Rsk2 and Emi1 contributes to the metaphase arrest of mouse oocytes.

Authors:  Maria Paola Paronetto; Ezio Giorda; Rita Carsetti; Pellegrino Rossi; Raffaele Geremia; Claudio Sette
Journal:  EMBO J       Date:  2004-11-04       Impact factor: 11.598

4.  RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

Authors:  C F Wu; S Liu; Y-C Lee; R Wang; S Sun; F Yin; W G Bornmann; L-Y Yu-Lee; G E Gallick; W Zhang; S-H Lin; J Kuang
Journal:  Oncogene       Date:  2013-05-27       Impact factor: 9.867

5.  Oncogenic Ras suppresses Cdk1 in a complex manner during the incubation of activated Xenopus egg extracts.

Authors:  Tun-Lan Huang; Jerry P Pian; Bin-Tao Pan
Journal:  Arch Biochem Biophys       Date:  2013-01-29       Impact factor: 4.013

6.  p90Rsk is not involved in cytostatic factor arrest in mouse oocytes.

Authors:  Julien Dumont; Muriel Umbhauer; Pascale Rassinier; André Hanauer; Marie-Hélène Verlhac
Journal:  J Cell Biol       Date:  2005-04-18       Impact factor: 10.539

7.  A requirement for MAP kinase in the assembly and maintenance of the mitotic spindle.

Authors:  Melinda M Horne; Thomas M Guadagno
Journal:  J Cell Biol       Date:  2003-06-23       Impact factor: 10.539

8.  A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer.

Authors:  Narayanasamy Arul; Yong-Yeon Cho
Journal:  Front Oncol       Date:  2013-08-05       Impact factor: 6.244

9.  Hydrogen Sulfide Impairs Meiosis Resumption in Xenopus laevis Oocytes.

Authors:  Armance Gelaude; Sylvain Slaby; Katia Cailliau; Matthieu Marin; Arlette Lescuyer-Rousseau; Caroline Molinaro; Jan Nevoral; Veronica Kučerová-Chrpová; Marketa Sedmikova; Jaroslav Petr; Alain Martoriati; Jean-François Bodart
Journal:  Cells       Date:  2020-01-17       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.